BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26519290)

  • 1. Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.
    Paciello R; Urbanowicz RA; Riccio G; Sasso E; McClure CP; Zambrano N; Ball JK; Cortese R; Nicosia A; De Lorenzo C
    J Gen Virol; 2016 Jan; 97(1):82-94. PubMed ID: 26519290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.
    Fukasawa M; Nagase S; Shirasago Y; Iida M; Yamashita M; Endo K; Yagi K; Suzuki T; Wakita T; Hanada K; Kuniyasu H; Kondoh M
    J Virol; 2015 May; 89(9):4866-79. PubMed ID: 25673725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of anti-claudin-1 antibodies as candidate therapeutics against hepatitis C virus.
    Yamashita M; Iida M; Tada M; Shirasago Y; Fukasawa M; Nagase S; Watari A; Ishii-Watabe A; Yagi K; Kondoh M
    J Pharmacol Exp Ther; 2015 Apr; 353(1):112-8. PubMed ID: 25628391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibodies against Occludin Completely Prevented Hepatitis C Virus Infection in a Mouse Model.
    Shimizu Y; Shirasago Y; Kondoh M; Suzuki T; Wakita T; Hanada K; Yagi K; Fukasawa M
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29437969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes.
    Fofana I; Krieger SE; Grunert F; Glauben S; Xiao F; Fafi-Kremer S; Soulier E; Royer C; Thumann C; Mee CJ; McKeating JA; Dragic T; Pessaux P; Stoll-Keller F; Schuster C; Thompson J; Baumert TF
    Gastroenterology; 2010 Sep; 139(3):953-64, 964.e1-4. PubMed ID: 20685314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolate-dependent use of claudins for cell entry by hepatitis C virus.
    Haid S; Grethe C; Dill MT; Heim M; Kaderali L; Pietschmann T
    Hepatology; 2014 Jan; 59(1):24-34. PubMed ID: 23775920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo combination of human anti-envelope glycoprotein E2 and -Claudin-1 monoclonal antibodies for prevention of hepatitis C virus infection.
    Mailly L; Wrensch F; Heydmann L; Fauvelle C; Brignon N; Zeisel MB; Pessaux P; Keck ZY; Schuster C; Fuerst TR; Foung SKH; Baumert TF
    Antiviral Res; 2019 Feb; 162():136-141. PubMed ID: 30599173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape.
    Colpitts CC; Tawar RG; Mailly L; Thumann C; Heydmann L; Durand SC; Xiao F; Robinet E; Pessaux P; Zeisel MB; Baumert TF
    Gut; 2018 Apr; 67(4):736-745. PubMed ID: 28360099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Claudin 1 as a target for anti-hepatitis C virus strategy].
    Fukasawa M
    Yakugaku Zasshi; 2014; 134(5):635-40. PubMed ID: 24790046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
    Lacek K; Vercauteren K; Grzyb K; Naddeo M; Verhoye L; Słowikowski MP; Fafi-Kremer S; Patel AH; Baumert TF; Folgori A; Leroux-Roels G; Cortese R; Meuleman P; Nicosia A
    J Hepatol; 2012 Jul; 57(1):17-23. PubMed ID: 22414763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Claudin-targeted drug development using anti-claudin monoclonal antibodies to treat hepatitis and cancer.
    Hashimoto Y; Fukasawa M; Kuniyasu H; Yagi K; Kondoh M
    Ann N Y Acad Sci; 2017 Jun; 1397(1):5-16. PubMed ID: 28415141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
    Bose M; Mullick R; Das S; Das S; Karande AA
    Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential expression of candidate virus receptors in human T lymphocytes prone or resistant to infection with patient-derived hepatitis C virus.
    Sarhan MA; Chen AY; Michalak TI
    PLoS One; 2013; 8(4):e62159. PubMed ID: 23626783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry.
    Riva L; Song OR; Prentoe J; Helle F; L'homme L; Gattolliat CH; Vandeputte A; Fénéant L; Belouzard S; Baumert TF; Asselah T; Bukh J; Brodin P; Cocquerel L; Rouillé Y; Dubuisson J
    J Virol; 2018 May; 92(10):. PubMed ID: 29491159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies.
    Zeisel MB; Fofana I; Fafi-Kremer S; Baumert TF
    J Hepatol; 2011 Mar; 54(3):566-76. PubMed ID: 21146244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saikosaponin b2 is a naturally occurring terpenoid that efficiently inhibits hepatitis C virus entry.
    Lin LT; Chung CY; Hsu WC; Chang SP; Hung TC; Shields J; Russell RS; Lin CC; Li CF; Yen MH; Tyrrell DL; Lin CC; Richardson CD
    J Hepatol; 2015 Mar; 62(3):541-8. PubMed ID: 25450204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.
    Catanese MT; Graziani R; von Hahn T; Moreau M; Huby T; Paonessa G; Santini C; Luzzago A; Rice CM; Cortese R; Vitelli A; Nicosia A
    J Virol; 2007 Aug; 81(15):8063-71. PubMed ID: 17507483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-hepatitis C virus strategy targeting host entry factor claudin-1].
    Fukasawa M
    Uirusu; 2015; 65(2):245-254. PubMed ID: 27760923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tight junction proteins claudin-1, -6, and -9 are entry cofactors for hepatitis C virus.
    Meertens L; Bertaux C; Cukierman L; Cormier E; Lavillette D; Cosset FL; Dragic T
    J Virol; 2008 Apr; 82(7):3555-60. PubMed ID: 18234789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of a human-mouse chimeric antibody against the extracellular domain of claudin-1 for cancer therapy using a mouse model.
    Hashimoto Y; Tada M; Iida M; Nagase S; Hata T; Watari A; Okada Y; Doi T; Fukasawa M; Yagi K; Kondoh M
    Biochem Biophys Res Commun; 2016 Aug; 477(1):91-95. PubMed ID: 27286708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.